Viral Oncology: Basic Science and Clinical Applications

A comprehensive look at the latest research findings and clinical applications of oncogenic viruses
Written by a panel of academic experts, Viral Oncology is the first self–contained and comprehensive book to present both scientific and clinical information on viruses linked to some of the most important human cancers. Readers can turn to this book for the most in–depth and up–to–date coverage of: HPV–associated cancers; molecular events associated with HPV–induced human cancer; the role of the HPV E6 oncoprotein in malignant progression; virus association with brain tumors; involvement of the polyomavirus JCV in colorectal cancer; possibleassociation of BKV with prostate cancer; oncogenic transformation bypolyomavirus large T antigen; SV40 and human cancer; SV40 and mesothelioma; molecular immunology of hepatitis B–associated viral cancer; hepatitis B vaccine and hepatocellular carcinoma; pathogenesis of acute and chronic hepatitis Cvirus infection; molecular mechanisms of hepatitis C virus–induced cellulartransformation; clinical aspects of HTLV–1 associated cancer; oncogenic potential of the HTLV–1 tax protein; HIV–associated malignancy; HIV–related lymphoma; biology and epidemiology of HHV–8; the role of KSHV in pathogenesis of Kaposi′ssarcoma; molecular pathobiology of EBV infection; and EBV as a pathogen.
Several chapters are devoted to the basic science of oncogenic viruses for thestudy of their pathogenesis, drug development, and employment of viral vectorsfor vaccine and gene therapy. The book also includes complementary clinically based chapters describing natural courses and treatments. Additionally, bonusclinical materials are embedded within chapters and an easy–to–use indexcompletes the book.
Viral Oncology is an essential resource for clinical and research oncologists in medical facilities and biological research laboratories; clinicians and scientists working in related biomedical areas; medical students working toward a first or higher degree in the life sciences and other biomedical fields; and pharmaceutical scientists and developers.

Spis treści:
Foreword.
Preface.
Contributors.
1 HUMAN PAPILLOMAVIRUS–ASSOCIATED CANCERS (Rachel A. Katzenellenbogen and Denise A. Galloway).
2 MOLECULAR EVENTS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS–INDUCED HUMAN CANCERS (Amy Baldwin and Karl Münger).
3 THE ROLE OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEIN IN MALIGNANT PROGRESSION (Miranda Thomas, David Pim, and Lawrence Banks).
4 JC VIRUS ASSOCIATION WITH BRAIN TUMORS: THE ROLE OF T ANTIGEN AND INSULIN–LIKE GROWTH FACTOR 1 IN DNA REPAIR FIDELITY (Krzysztof Reiss, Kamel Khalili, and Luis Del Valle).
5 INVOLVEMENT OF THE POLYOMAVIRUS, JC VIRUS, IN COLORECTAL CANCER (C. Richard Boland, Luigi Ricciardiello, and Ajay Goel).
6 POSSIBLE ASSOCIATION OF BK VIRUS WITH PROSTATE CANCER (Michael J. Imperiale and Dweepanita Das).
7 ONCOGENIC TRANSFORMATION BY POLYOMAVIRUS LARGE T ANTIGEN (Abhilasha V. Rathi and James M. Pipas).
8 SIMIAN VIRUS 40, HUMAN INFECTIONS, AND CANCER: EMERGING CONCEPTS AND CAUSALITY CONSIDERATIONS (Janet S. Butel).
9 SIMIAN VIRUS 40 AND MESOTHELIOMA (Natalya Baranova and Michele Carbone).

10 MOLECULAR IMMUNOBIOLOGY OF HEPATITIS B–ASSOCIATED VIRAL CANCER (Timothy M. Block and Anand S. Mehta).
11 HEPATITIS B VACCINE AND HEPATOCELLULAR CARCINOMA (Mei–Hwei Chang and Ding–Shinn Chen).
12 PATHOGENESIS OF ACUTE AND CHRONIC HEPATITIS C VIRUS INFECTION (Mark A. Feitelson, Helena M.G.P.V. Reis, Jingbo Pan, and Bill Sun).
13 MOLECULAR MECHANISMS OF HEPATITIS C VIRUS–INDUCED CELLULAR TRANSFORMATION (Donna Sir and Jing–Hsiung James Ou).
14 CLINICAL ASPECTS OF HTLV–1–ASSOCIATED CANC ER (Masao Matsuoka).
15 ONCOGENIC POTENTIAL OF THE HTLV–1 TAX PROTEIN (Susan J. Marriott).
16 HIV–1–ASSOCIATED MALIGNANCY: BASIC AND CLINICAL ASPECTS (Melissa Agsalda and Bruce Shiramizu).
17 HIV–RELATED LYMPHOMA (Giulia De Falco, Cristiana Bellan, Stefano Lazzi, and Lorenzo Leoncini).
18 BIOLOGY AND EPIDEMIOLOGY OF HHV–8 (Veenu Minhas and Charles Wood).
19 THE ROLE OF KSHV IN PATHOGENESIS OF KAPOSI’S SARCOMA (Gary S. Hayward, Donald J. Alcendor, and Ravit Arav–Boger).
20 MOLECULAR PATHOBIOLOGY OF EBV INFECTION (Joseph S. Pagano).
21 EPSTEIN–BARR VIRUS AS A PATHOGEN (Wasim A. Dar and Bill Sugden).
Index.

Okładka tylna:
A comprehensive look at the latest research findings and clinical applications of oncogenic viruses
Written by a panel of academic experts, Viral Oncology is the first self–contained and comprehensive book to present both scientific and clinical information on viruses linked to some of the most important human cancers. Readers can turn to this book for the most in–depth and up–to–date coverage of: HPV–associated cancers; molecular events associated with HPV–induced human cancer; the role of the HPV E6 oncoprotein in malignant progression; virus association with brain tumors; involvement of the polyomavirus JCV in colorectal cancer; possibleassociation of BKV with prostate cancer; oncogenic transformation bypolyomavirus large T antigen; SV40 and human cancer; SV40 and mesothelioma; molecular immunology of hepatitis B–associated viral cancer; hepatitis B vaccine and hepatocellular carcinoma; pathogenesis of acute and chronic hepatitis Cvirus infection; molecular mechanisms of hepatitis C virus–induced cellulartransformation; clinical aspects of HTLV–1 associated cancer; oncogenic potential of the HTLV–1 tax protein; HIV–ass ociated malignancy; HIV–related lymphoma; biology and epidemiology of HHV–8; the role of KSHV in pathogenesis of Kaposi′ssarcoma; molecular pathobiology of EBV infection; and EBV as a pathogen.
Several chapters are devoted to the basic science of oncogenic viruses for thestudy of their pathogenesis, drug development, and employment of viral vectorsfor vaccine and gene therapy. The book also includes complementary clinically based chapters describing natural courses and treatments. Additionally, bonusclinical materials are embedded within chapters and an easy–to–use indexcompletes the book.
Viral Oncology is an essential resource for clinical and research oncologists in medical facilities and biological research laboratories; clinicians and scientists working in related biomedical areas; medical students working toward a first or higher degree in the life sciences and other biomedical fields; and pharmaceutical scientists and developers.